MedPath

Transcranial Direct Current Simulation in Chronic Migraine

Phase 1
Conditions
Migraine Disorders
Interventions
Device: TDCS
Registration Number
NCT02817139
Lead Sponsor
Federal University of Paraíba
Brief Summary

This study is a pilot, double-blind, placebo-controlled, randomized trial aiming to compare the effects of transcranial direct current stimulation in Chronic Migraine.

Detailed Description

The patients will be randomized into 1 of 3 groups: active tDCS over primary motor cortex, active tDCS over prefrontal cortex, sham tDCS. Each group will receive treatment for 20 minutes a day, 3 days a week for 4 weeks.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
15
Inclusion Criteria
  • patients with a clinical diagnosis of chronic migraine according to the International Classification of Headaches Disorders (ICHD-3 beta) of the International Headache Society, with an established headache history occurring on 15 or more days per month-however, for at least 1 year, instead of only 3 months, as defined in the International Headache Society (IHS) guidelines.
Exclusion Criteria
  • headache attributable to some pathological condition, associated neurologic or neuropsychiatric disease, use of central nervous system modulating drugs, pregnancy, metallic head implants, and use of a cardiac pacemaker.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
sham tDCS over primary motor cortexTDCSDuration: 20 minutes; The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham; Placement: left primary motor cortex.
active tDCS over primary motor cortexTDCSDuration: 20 minutes; Intensity: 2 mA; Placement: left primary motor cortex.
active tDCS over prefrontal cortexTDCSDuration: 20 minutes; Intensity: 2 mA; Placement: left prefrontal cortex.
Primary Outcome Measures
NameTimeMethod
Change in quality of life associate to migraine assessed on the Headache Impact Test-6 (HIT-6)Baseline (week 1) and Endpoint (week 4)
Secondary Outcome Measures
NameTimeMethod
Change in pain assessed on the Visual Analogue Scale (VAS)Baseline (week 1) and Endpoint (week 4)
Side Effects QuestionnaireFrom date of first neurostimulation until the date of last neurostimulation, , assessed up to 1 month
Change in quality of life assessed on the Medical Outcomes Study 36 - Item Short - Form Health Survey(SF-36)Baseline (week 1) and and Endpoint (week 4)

Trial Locations

Locations (1)

Suellen Andrade

🇧🇷

João Pessoa, PB, Brazil

© Copyright 2025. All Rights Reserved by MedPath